Cargando…

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival

BACKGROUND: In 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of GBMs are IDH-wild-type. Nomograms are useful tools for individualized estimation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gittleman, Haley, Cioffi, Gino, Chunduru, Pranathi, Molinaro, Annette M, Berger, Mitchel S, Sloan, Andrew E, Barnholtz-Sloan, Jill S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777501/ https://www.ncbi.nlm.nih.gov/pubmed/31608326 http://dx.doi.org/10.1093/noajnl/vdz007

Ejemplares similares

Prognostic risk stratification of gliomas using deep learning in digital pathology images
por: Chunduru, Pranathi, et al.
Publicado: (2022)

Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study
por: Malay, Sindhoosha, et al.
Publicado: (2020)

Glioma stem cells activate platelets by plasma-independent thrombin production to promote glioblastoma tumorigenesis
por: Sloan, Anthony R, et al.
Publicado: (2022)

Proteins inform survival-based differences in patients with glioblastoma
por: Stetson, L C, et al.
Publicado: (2020)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma
por: Li, Xianqi, et al.
Publicado: (2022)

Sexually dimorphic impact of the iron-regulating gene, HFE, on survival in glioblastoma
por: Nesterova, Darya S, et al.
Publicado: (2020)

Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database
por: Hodges, Tiffany R, et al.
Publicado: (2021)

Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
por: Ehret, Felix, et al.
Publicado: (2023)

Gliomas display distinct sex-based differential methylation patterns based on molecular subtype
por: Johansen, Mette L, et al.
Publicado: (2020)

A Case of Glioblastoma, Isocitrate Dehydrogenase Wild Type, With Widely Disseminated Osseous Metastasis
por: Conte, Brianna, et al.
Publicado: (2022)

Treatment Outcomes for Primary Hepatic Angiosarcoma: National Cancer Database Analysis 2004–2014
por: Mangla, Ankit, et al.
Publicado: (2022)

Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults
por: King-Stephens, David
Publicado: (2022)

The T2-FLAIR mismatch sign in glioblastoma, isocitrate dehydrogenase wild-type A case report
por: Nishimura, Shunsuke, et al.
Publicado: (2023)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

A Descriptive, Longitudinal Study of Quality of Life and Perceived Health Needs in Patients With Head and Neck Cancer
por: Sandstrom, S. Kate, et al.
Publicado: (2016)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect
por: Gibson, David, et al.
Publicado: (2023)

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology
por: Pekmezci, Melike, et al.
Publicado: (2021)

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
por: Oh, Sejin, et al.
Publicado: (2020)

Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy
por: Zhao, Chao, et al.
Publicado: (2021)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors
por: Herrgott, Grayson A, et al.
Publicado: (2022)

Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma
por: Koh, Sabrina P., et al.
Publicado: (2017)

Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma
por: Wang, Shouchao, et al.
Publicado: (2022)

A PTPmu Biomarker is Associated with Increased Survival in Gliomas
por: Johansen, Mette L., et al.
Publicado: (2019)

GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data
por: Ajaib, Shoaib, et al.
Publicado: (2023)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns
por: Lo, Chung-Ming, et al.
Publicado: (2020)

A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma
por: Wang, Lei-Ming, et al.
Publicado: (2021)

Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex
por: Thierheimer, Marisa, et al.
Publicado: (2023)

A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease
por: Gittleman, Haley R., et al.
Publicado: (2016)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Clinical implications of hypoxia-inducible factor-1α and caveolin-1 overexpression in isocitrate dehydrogenase-wild type glioblastoma multiforme
por: Chen, Wenli, et al.
Publicado: (2019)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Favorable prognostic impact of phosphatase and tensin homolog alterations in wild-type isocitrate dehydrogenase and telomerase reverse transcriptase promoter glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2023)

Changes in survival over time for primary brain and other CNS tumors in the United States, 2004–2017
por: Cioffi, Gino, et al.
Publicado: (2022)

Multireceptor targeting of glioblastoma
por: Sharma, Puja, et al.
Publicado: (2020)

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma
por: Ding, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j35441tvv57ribt59uksliiql7